Clinical article · Specialties, Medicines and results

CYP3A4 interactions that harm patients: statins, macrolides and anticoagulants

Written for
Hospital physicians, clinical pharmacists and residents
Reading time
7 minutes
Published
Updated

Written by the Sana Health team for clinicians. It summarises published guidance, is not a guideline and has not been peer reviewed. Check current local protocols before acting.

Key points

  • CYP3A4 metabolises many commonly used drugs, so one inhibitor or inducer added for a few days can change exposure to several of them at once.
  • Clarithromycin, erythromycin, most azole antifungals, diltiazem, verapamil and ritonavir inhibit CYP3A4; rifampicin, carbamazepine, phenytoin and St John's wort induce it.
  • Simvastatin, lovastatin and atorvastatin are affected by CYP3A4 inhibition, whereas pravastatin, rosuvastatin and pitavastatin largely are not.
  • Apixaban and rivaroxaban depend on CYP3A4 and P-glycoprotein, and antiplatelets, NSAIDs and SSRIs add bleeding risk to any oral anticoagulant.
  • Induction takes days to develop and to wear off, so stopping an inducer can raise the levels of other drugs.
  • The simplest fix is often a non-interacting alternative, or a short pause of the affected drug.

Why CYP3A4 matters

CYP3A4, in the liver and the gut wall, metabolises a large share of commonly prescribed drugs, and its activity varies widely between patients [1]. Inhibition takes effect within days and raises exposure to every drug that depends on the enzyme; induction develops more slowly and lowers exposure, sometimes to the point of treatment failure. Harm is most likely when the affected drug has a narrow therapeutic index or dose-dependent toxicity, and when the patient is older, frail, has impaired kidney or liver function, or takes many medicines. Short antibiotic and antifungal courses are a common trigger, because they are added to long-standing regimens by teams who did not start them.

The usual culprits

DrugEffectAlso note
ClarithromycinStrong CYP3A4 inhibitorAlso inhibits P-glycoprotein and prolongs the QT interval
ErythromycinModerate CYP3A4 inhibitorProlongs the QT interval
AzithromycinLittle CYP3A4 inhibitionQT prolongation still needs considering
Itraconazole, ketoconazole, posaconazole, voriconazoleStrong CYP3A4 inhibitorsFluconazole is a moderate inhibitor and also inhibits CYP2C9
Ritonavir and cobicistat, including nirmatrelvir/ritonavirStrong CYP3A4 inhibitorsAlso affect CYP2D6 and P-glycoprotein [12]
Diltiazem and verapamilModerate CYP3A4 inhibitorsAdditive slowing of heart rate and conduction
RifampicinStrong inducerEffect persists after it is stopped
Carbamazepine, phenytoin, phenobarbital, St John's wortInducersSt John's wort is often not recorded as a medicine [8]

Statins and macrolides

The main risk of statins is myopathy and, rarely, rhabdomyolysis, and it rises with drugs that increase their systemic exposure [2, 3]. Potent CYP3A4 inhibitors substantially raise concentrations of simvastatin, lovastatin and atorvastatin; fluvastatin is metabolised by CYP2C9, while pravastatin, rosuvastatin and pitavastatin are unaffected by inhibition of either enzyme [4]. In healthy volunteers, CYP3A4 inhibitors including verapamil and itraconazole caused no significant change in pravastatin exposure [2]. A systematic review of clarithromycin with individual statins, drawing on case reports, observational and pharmacokinetic studies, sets out management for each combination [5].

  • Simvastatin or lovastatin with clarithromycin, itraconazole, ketoconazole, posaconazole or a ritonavir-boosted regimen: avoid; US product labelling contraindicates these combinations.
  • Atorvastatin with a strong inhibitor: use with caution and within the label's dose limit, or pause it.
  • For a short course of clarithromycin, pausing the statin for the course is usually the simplest option, or choose an antibiotic without the interaction.
  • For long-term co-prescription, switch to pravastatin or rosuvastatin.
  • Ask about muscle pain, weakness and dark urine, and check creatine kinase if they occur.

Other drugs at risk

Clarithromycin raises exposure to dihydropyridine calcium channel blockers such as amlodipine and nifedipine, which can cause hypotension and oedema, particularly in older patients. Colchicine has a narrow therapeutic index with no clear line between toxic and lethal doses, and unintentional toxicity is common and often serious [6]; its combination with clarithromycin or other strong CYP3A4 and P-glycoprotein inhibitors is best avoided, especially with kidney or liver impairment. Opioids are affected in both directions: inhibitors increase exposure to oxycodone and fentanyl, while rifampicin greatly reduces oxycodone concentrations [7]. Tacrolimus and ciclosporin levels rise with inhibitors and fall with inducers; St John's wort taken with ciclosporin caused acute rejection in two heart transplant recipients [8].

Anticoagulants

Warfarin interacts mainly through CYP2C9, which clears its more potent S-isomer, but CYP3A4 and CYP1A2 inhibitors and inducers can also change the INR [10]. Drugs that modify P-glycoprotein may interact with all direct oral anticoagulants (DOACs), and CYP3A4 modifiers with apixaban and rivaroxaban. Antiplatelet drugs, NSAIDs and serotonergic drugs such as SSRIs increase bleeding with any oral anticoagulant [9]. Although DOACs need no routine monitoring, drug interactions are an important contributor to their bleeding risk [11].

  • Combined strong CYP3A4 and P-glycoprotein inhibitors (for example itraconazole, ketoconazole or ritonavir): follow the product label, which advises dose reduction or avoidance for apixaban and rivaroxaban.
  • Clarithromycin with apixaban or rivaroxaban: exposure rises, although labelling does not require a dose change for every such combination; choose a non-interacting antibiotic where possible, or monitor closely for bleeding.
  • Strong inducers (rifampicin, carbamazepine, phenytoin, St John's wort): avoid with DOACs, because levels can fall enough to lose protection.
  • Warfarin: check the INR soon after starting or stopping any interacting drug.

A worked example

A patient taking simvastatin 40 mg, amlodipine 10 mg and apixaban 5 mg twice daily is prescribed clarithromycin for 7 days. Each regular medicine is affected:

  1. Simvastatin: contraindicated with clarithromycin. Withhold it for the course and restart afterwards, or use azithromycin if it suits the infection.
  2. Amlodipine: exposure rises; check blood pressure and ask about dizziness and ankle swelling during the course.
  3. Apixaban: clarithromycin raises its exposure. US labelling does not require a dose change for this particular combination, but many clinicians prefer an antibiotic without the interaction, and if clarithromycin is used the patient should be watched for bleeding.
  4. Review the QT interval and other QT-prolonging drugs, and record the restart plan for the statin.

Managing an interaction

  1. Ask whether the interacting drug is needed, or whether an alternative without the interaction would do.
  2. For a short course, pause the affected drug if that is safe; for long-term treatment, switch to a non-interacting agent.
  3. If both must continue, adjust the dose as the label directs and monitor: drug levels for tacrolimus, INR for warfarin, blood pressure, symptoms and creatine kinase.
  4. Remember the offset: inhibition fades within days of stopping the inhibitor, whereas induction can persist for days to weeks, and levels of affected drugs rise as it wears off.
  5. Record the change, the reason and any restart date in the notes and the discharge summary.

Interaction severity depends on dose, duration and the patient. Check the local formulary or an interaction resource, and remember that licensed recommendations differ between countries.

How Sana Health helps

The Medication Safety engine checks the full list and the drug being added, explains each interaction by mechanism, such as CYP3A4 or P-glycoprotein inhibition, and grades it as contraindicated, major, moderate or minor with how quickly it matters. Its Problems Found table puts the most serious issue first with the action for each, followed by a corrected regimen and a monitoring plan. When named medicines are involved, US product labels from DailyMed are attached and treated as the authority on contraindications, and doses are to be confirmed against the local formulary.

Questions

Which statins can be used with clarithromycin?

Pravastatin, rosuvastatin and pitavastatin are not significantly affected by CYP3A4 inhibition and are the usual choices when a statin must continue alongside a strong inhibitor. Simvastatin and lovastatin should not be combined with clarithromycin, and atorvastatin needs caution and a dose limit. For a short antibiotic course, pausing the statin is often simplest.

Is azithromycin safer than clarithromycin for patients on interacting drugs?

For CYP3A4 interactions, usually yes, because azithromycin inhibits the enzyme very little. It still prolongs the QT interval, so the whole regimen and the ECG need review, and the choice must suit the infection being treated.

How long does enzyme induction last after rifampicin is stopped?

Induction builds over days and fades gradually after the inducer is stopped, often over a couple of weeks. Doses of affected drugs that were increased need review, with levels or the INR checked as the effect wears off.

References

  1. Drug metabolism and variability among patients in drug response (opens in a new tab)N Engl J Med, 2005
  2. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors (opens in a new tab)Am J Cardiol, 2004
  3. Safety of statins: focus on clinical pharmacokinetics and drug interactions (opens in a new tab)Circulation, 2004
  4. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins (opens in a new tab)Expert Opin Drug Metab Toxicol, 2020
  5. Interaction potential between clarithromycin and individual statins-A systematic review (opens in a new tab)Basic Clin Pharmacol Toxicol, 2020
  6. Colchicine poisoning: the dark side of an ancient drug (opens in a new tab)Clin Toxicol (Phila), 2010
  7. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone (opens in a new tab)Anesthesiology, 2009
  8. Clinical relevance of St. John's wort drug interactions revisited (opens in a new tab)Br J Pharmacol, 2020
  9. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions (opens in a new tab)Blood, 2018
  10. Drug Interactions Affecting Oral Anticoagulant Use (opens in a new tab)Circ Arrhythm Electrophysiol, 2022
  11. Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week (opens in a new tab)J Am Coll Cardiol, 2020
  12. Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week (opens in a new tab)J Am Coll Cardiol, 2022